The state of the vasodilator systems in congestive heart failure is poorly defined. Plasma atrial natriuretic peptide is increased, whereas endothelium derived relaxing factor activity can be decreased. Atrial natriuretic peptide and endothelium derived relaxing factor both cause vascular relaxation by generating cyclic guanosine monophosphate (cGMP), by activating the particulate and the soluble guanylate cyclase, respectively. This study examines the biological effects of atrial natriuretic peptide and endothelium derived relaxing factor in experimental heart failure by assessing the plasma, urinary, and tissue concentrations of their common second messenger cGMP. Methods: Myocardial infarctions (n=3 1) were induced and sham operations (n=25) were performed on Wistar rats, and the rats were monitored for three months. Aortic and pulmonary cGMP contents were measured, as the aorta is mainly matrix and smooth muscle cells, and the lung is particularly rich in capillaries, hence in endothelial cells. The concentrations of the other second messenger cyclic adenosine monophosphate (CAMP) was also determined, as were those of cGMP dependent protein kinase in the arteries. Results: 17 of the 31 rats with myocardial infarction had oedema. The total heart weight to body weight ratio and the ratio of the myocardium haemodynamically upstream from the infarcted left ventricle to body weight were increased in proportion to the infarct size. Plasma atrial natriuretic peptide and plasma and urinary cGMP concentrations were increased in proportion to the degree of heart failure (peO.0001). The pulmonary cGMP concentration was significantly higher in the rats with myocardial infarction than in the control group (p<O.OOO 1). Pulmonary cGMP concentrations were correlated with the plasma concentrations of atrial natriuretic peptide and cGMP (r2=0.59 and 0.66 respectively, pc0.0001). The cGMP, CAMP, and cGMP, and cGMP dependent kinase concentrations in the aortic wall of rats with myocardial infarctions were the same as in control rats.
C accompanied by abnormalities of vasomotor tone.' Enhanced vasoconstriction at rest and impaired responsiveness to vasodilatory stimuli, such as exercise and ischaemia, have been attributed to raised sodium and water in the arterial wall, intrinsic abnormalities of the vascular smooth muscle, and neurohumoral Both circulating vasoconstrictor (sympathetic adrenergic and renin angiotensin systems) and vasodilator (atrial natriuretic factor) systems are activated in heart failure."' Atrial natriuretic peptide is released from cardiac myocytes and promotes peripheral vasodilation, natriuresis, and diuresis.' The vascular endothelium releases vasoactive substances that play a major part in the control of vasomotor tone.9 Endothelium derived relaxing factor, which is nitric oxide (NO) or a labile nitroso compound, promotes local vasodilation in both conduit and resistance vessel^.'^'^ Atrial natriuretic peptide and NO activate the particulate and soluble guanylate cyclase respectively, and these generate cyclic guanosine monophosphate (CGMP).'~ '' This common second messenger causes smooth muscle relaxation. Cyclic adenosine monophosphate (CAMP) mediates the effect of p adrenergic stimulation, prostacyclin, etc. " Thus cAMP is the other cyclic nucleotide second messenger involved in the vascular smooth muscle relaxation.
During heart failure, the heart releases large amounts of atrial natriuretic peptide in response to overload." l9 The efficacy of atrial natriuretic peptide seems to be dramatically blunted, however, in this pathophysiological state.*&" Abnormalities of the endothelium dependent vasodilation may also contribute to the increased vasomotor tone in congestive heart failure.2s-2s The present study was performed to investigate the relation between plasma, urine, and tissue (aorta and lung) concentrations of cGMP, the plasma atrial natriuretic peptide concentration, and the severity of heart failure in an experimental model of chronic heart failure. The concentrations of cAMP were also determined, as were those of cGMP dependent protein kinase in the arteries. Finally, the effect of exogenous atrial natriuretic peptide on plasma and tissue cGMP in normal rats was studied. 
Methods

Experimental design
The procedures followed in the care and euthanasia of the study animals were in accordance with the European Community standards on the care and use of laboratory animals (Minist&re de ]'Agriculture, France; authorisation No 00577, 30 April 1989). Normotensive male Wistar rats (Iffa Credo, Lyon, France) weighing 300-320 g were used. Left ventricular infarction was produced by ligation of the left descending anterior coronary artery under ether anaesthesia as described by Fishbein et a/29 and Pfeffer et al." The left descending anterior coronary artery was ligated proximally to obtain a large infarct leading to animals with decompensated heart failure. Controls were sham operated by a similar procedure (thordcotomy) without coronary ligation. Systolic blood pressure and body weight were measured weekly by the tail cuff method (W+W electronic recorder 8005, Apelab, Bagneux, France) and the animals were examined twice weekly for three months. At the end of the first month, each rat was placed in a metabolic cage and urine was collected for 15 hours. Although the study was designed to examine the disturbances of the peripheral circulation that occur in severe and decompensated heart failure,'-' this stage is rapidly lethal, making it difficult to obtain animals with decompensated heart failure. To avoid losing most of these rats, those showing overt signs of heart failure were killed after the first month if they showed two of the three following signs: blood pressure impossible to measure, no weight gain or weight loss during one week, breathlessness. A control rat was killed on the same day. Because anaesthesia induces changes in circulating hormone concentrations, rats were killed by decapitation to allow hormonal measurements. Blood samples were collected into prechilled 10 ml tubes containing 2 m g m P sodium EDTA, 10 pl phenylmethyl sulphonyl fluoride in ethanol (4.25 mgm-'), and 25 pl aprotonin (200 000 protease inhibitor units [PIU]m-l). These samples were centrifuged for 10 minutes at 3000 g, and the plasma was removed and frozen at -70°C. At the same time, arteries and organs were rapidly excised in the order: abdominal aorta plus iliac arteries, thoracic aorta and the lung (within 3 minutes after decapitation for all organs). The samples were rinsed in cold phosphate buffered saline, frozen in liquid nitrogen, and stored at -70°C. The heart was excised and weighed. The left ventricle was separated from the two atria and the right ventricle was weighed.
Determination of infarct size
The left ventricle was opened with an incision along the septum from base to apex. Both ventricles were rinsed, blotted dry, and weighed. Myocardial infarct size was measured as described by Chien et al. I9 Incisions were made in the left ventricle so that tissue could be pressed flat. The circumferences of the left ventricle and the region of infarction on both the endocardial and epicardial surfaces were outlined on a clear plastic sheet. Infarct size was calculated and expressed as a percentage of left ventricle surface area, based on the weight of the areas on the sheet. An average of endocardial and epicardial surface areas is reported.
The level of heart failure was further defined by dividing the rats with myocardial infarcts into two subgroups according to one major criterion, oedema, and three minor criteria (heart weight -left ventricle index >1.5Xcontrol, infarction size 335%. urinary cGMP >3Xcontrol). Those rats showing oedema or the three minor criteria were assigned to the severe myocardial infarct subgroup. Rats showing two or fewer minor criteria were assigned to the moderate myocardial infarct subgroup.
Effect of intravenous atrial natriuretic peptide
Normotensive male Wistar rats weighing 300-320 g were used to study the effects of exogenous atrial natriuretic peptide on tissue cGMP. The rats were anaesthetised with inactin (100 mg.kg-') and the right jugular vein was cannulated with an elastomer catheter for injections and blood samples. The experimental protocol was then carried out on anaesthetised animals. After a control period of one hour, a bolus injection of 3 pg.kg-' of rat atrial natriuretic peptide (1-28, Peninsula) was given to five rats; the control rats (n=5) were given only saline vehicle. Five minutes after the bolus, a 4 ml blood sample was collected into prechilled 5 ml tubes containing 2 m g m -' sodium EDTA, 10 PI phenylmethyl sulphonyl fluoride in ethanol (4.25 mgm-I), and 25 pl aprotonin (200 OOO protease inhibitor units [PIUIm-') . At the same time, the abdominal aorta, thoracic aorta, and the lung were rapidly excised (total time of two to three minutes). They were rinsed in cold phosphate buffered saline, frozen in liquid nitrogen, and stored at -70°C.
Preparation of tissue samples
The thoracic aorta was divided into large proximal (about 30 mg) and small distal (about 20 mg) segments. The abdominal aorta plus iliac arteries were similarly divided into a large segment including the bifurcation and the two iliac arteries (about 25 mg) and the upper part of the abdominal aorta (about 15 mg). The large segments were homogenised in 10 vol buffer (20 mM KPO,, pH 7.0, plus 2 mM benzamidine) with an all glass homogeniser at 4°C for determination of the cGMP dependent concentration. The small segments were homogenised in 10 vol 0.1N HCI with an all glass homogeniser at 4°C for determination of cyclic nucleotides. A cortical segment of lung (about 100 mg) was homogenised in 10 vol 0.1N HCI with an all glass homogeniser at 4°C for determination of cyclic nucleotides. All the homogenates were centrifugated at 15 000 g for 30 minutes, and aliquots of the supernatants were stored at -20°C. Protein concentrations of all samples were determined by the Bio-Rad Coomassie brilliant blue (3-250 methods with bovine serum albumin as standard.
Determination of cGMP and CAMP concentrations
Polyclonal antibody against succinyl cGMP raised in rabbits was provided by Dr B Bucher (Strasbourg, France). The antigen was prepared by coupling succinyl cGMP to human serum albumin by the method of Steiner et al." Cross reactivity of the antiserum with CAMP was 0.02%. The radioligand "I-succinyl-cGMP tyrosine methyl ester was prepared by iodinating the succinyl-cGMP tyrosine methyl ester (Sigma) by the method of Greenwood et a/" with carrier free lZ5I (Amersham) . The iodination reaction products were separated on Sephadex (3-25 fine (Pharmacia LKB). Standard stock solutions of cGMP (40 pM) were prepared in water and the absorbance of the solution was routinely monitored spectrophotometrically (Uvikon 810P. Kontron). Standard dilutions (40-2560 pM) were made from the stock solution. The HCI extracts containing cGMP were determined radioimmunologically according to Cailla et a/" as modified by Honma et a/'4 to increase sensitivity by succinylating the cGMP before binding to the antibody. The sensitivity of the assay was 2 fmol per tube. The intra-assay reproducibility for duplicate determinations was calculated from 10 measurements of an unknown in the assay. The mean result was 21.8(SD 2.6) fmol. The coefficient of variation was 12%.
The plasma was deproteinised by adding ice cold ethanol to give a final suspension volume of 65% ethanol. The suspension was then centrifuged for 10 minutes at 3000 g . the supernatant was transferred to fresh tubes, and the extract evaporated to dryness under a stream of nitrogen at 60°C. The dried extracts were dissolved in assay buffer before analysis. Urinary cGMP was expressed as nmo1.100 g-' of body weight of urine collected for 15 hours.
Cyclic AMP was determined with a radioimmunoassay kit (RPA 508, Amersham).
Determination of plasma atrial narriuretic peptide
Plasma atrial natriuretic peptide was extracted on a C18 cartridge and determined by non-equilibrium radioimmunoassa with a double antibody to separate the free and bound fractions.' Peptide tracer was labelled with lZSI by a modified chloramine T method.32
Determination of cGMP dependent kinase concentration
The tissue concentration of cGMP dependent kinase was determined by an enzyme linked immunosorbent assay (ELISA) with affinity purified anti-cGMP kinase rabbit antibodies." Microtiter plates were coated with pure cGMP kinase for 16 hours at 4°C. The coating solution was removed by aspiration, and the residual binding sites were saturated by incubation with buffer A (20 mM KPO,, pH 7.5, 150 mM NaCI, 0.01% NaN,) containing 2% bovine serum albumin (BSA) pH 7.0, at room temperature for one hour. The plates were washed twice with buffer A containing 0.1 % BSA. The affinity purified rabbit antibodies were preincubated with three dilutions of tissue extracts or pure cGMP dependent kinase for 16 hours at 4°C. These probes were transferred to the plates and incubated for two hours at 4°C. The plates were then washed twice. A goat anti rabbit IgG-peroxidase conjugate was added and the plates incubated for one hour at room temperature. They were washed three times and substrate solution (0.4 mg/ml 1,2 phenylene diamine plus 0.001% H Z 0 2 in a phosphate citrate buffer, pH 5.0) was added. The reaction was stopped with 2N HCI after 15 minutes and the reaction product was measured at 492 nm. The cGMP-dependent kinase concentration was calculated as described previo~sly.'~
Statistical methods
Results are expressed as means(SEM). Differences in blood pressure and body weight were evaluated by ANOVA with repeated measures (comparison of the three groups). A non-paired test was used to compare the differences of infarct size between the two subgroups of myocardial infarction. One way analysis of variance was followed by the Scheffe F test to compare the effect of the pathophysiological condition on the different variables. Linear regression curves and correlation coefficients were obtained by the least squares method.
Results
Mortality, blood pressure, and body weight
The mortality was 28 of 59 rats with myocardial infarction and 1 of 26 sham operated rats. Seven rats with myocardial infarction (and seven controls) were killed early after the end of the first month because of overt signs of heart failure. A total of 31 rats with myocardial infarction and 25 sham operated rats survived to the end of the experiment. Induction of the myocardial infarction caused a significant fall in systolic blood pressure that persisted throughout the study (F 15.17, p<O.OOOl) (fig I) . The experimental procedures slowed the increase in body weight in these young rats. The rats with severe myocardial infarction were lighter than the control group throughout the experimental period (F 3.59, p<0.05) (table 1).
Heart variables and oedema (table 1 ) The total heart weight to body weight ratio was significantly greater in the myocardial infarction subgroups than in the sham operated rats (F 73.46, p<O.OOOl) . Both the absolute weights of the myocardium haemodynamically upstream from the infarcted left ventricle (the left atrium, right ventricle, and right atrium) and the ratios of their weights to body weight were significantly increased (F 85.05, p<O.OOOl). The infarction involved 29(1)% of the left ventricle in the rats with moderate myocardial infarction and 37( I)% in the rats with severe myocardial infarction (t=3.85, p<O.OOl). The infarct size was correlated with the total heart weight to body weight ratio (r2=0.37, p<0.0005, n=31), and with the ratio of the myocardium haemodynamically upstream from the infarcted left ventricle to body weight (r2=0.46, p<O.OOOl, n=3 1). Pleural effusion was present in 85% of the rats with severe myocardial infarction and was abundant (>2 ml with possible ascitis) in 40%.
Plasma and urine variables (table 2 )
The plasma conceDtration of atrial natriuretic peptide in rats with myocardial infarcts was significantly above that of the sham rats (F 67.1 I , p<O.OOOl) (table 2). The plasma atrial natriuretic peptide was correlated with the total heart to body weight ratio (r2=0.67, p<O.OOOl, n=56), the ratio of the myocardium weight haemodynamically upstream from the left ventricle to body weight (r2=0.65, p<O.OOOl, n=56), and with the infarction size (y=28.9x-89.6, r2=0.334, p<O.OOl, n=56). The plasma concentrations of cGMP were significantly increased in both groups of rats with heart failure (F 52.63, p<O.OOOl). There was a close correlation between plasma cGMP and plasma atrial natriuretic peptide (r'=0.72, p<O.OOOl, n=56). Plasma cAMP did not change in either group. Urinary cGMP was significantly raised in the model of heart failure (F 34.36, p<O.OOOl) and was closely correlated with plasma concentrations of atrial natriuretic peptide (r2=0.49, p<O.OOOl, n=56).
Tissue variables
The pulmonary cGMP concentration was significantly higher in the rats with myocardial infarcts than in the control group (F 11.13, p<O.OOOl) ( Table 2 shows the data from cGMP in the two subgroups as previously defined. The cAMP concentrations of the arterial wall and the lung remained unchanged in the rats with myocardial infarcts (table 3). The cGMP dependent kinase concentrations in segments of thoracic aorta and abdominal aorta plus iliac arteries from sham operated rats (n=8) and rats with severe myocardial infarction (n=8) were similar (table 3).
Effect of exogenous atrial natriuretic peptide (table 4)
Plasma atrial natriuretic peptide in anaesthetised rats given only saline vehicle was 332(36) pg/ml. Plasma atrial natriuretic peptide in rats given a bolus injection of 3 pg ANP/ kg was 2452(77 1) pg/ml. Exogenous atrial natriuretic peptide increased plasma and pulmonary cGMP content by about fivefold and 9.5-fold respectively. Bolus injection of 3 pg atrial natriuretic peptide.kg-' did not significantly influence thoracic or abdominal aortic cGMP content, however. 
Discussion
The state and the role of two major vasoconstrictor systems, the sympathetic adrenergic system and the renin angiotensin system, in the pathogenesis of the disturbances of the peripheral circulation have been extensively studied in heart failure.' ' Because of their more recent characterisation,'-" the state of the endogenous vasodilatory systems have been less thoroughly investigated. The increase in the plasma concentration of atrial natriuretic peptide in relation to the severity of heart failure was contirmed in our present study.' Fifty five per cent of the rats with myocardial infarction had oedema and thus provide a suitable model of decompensated heart failure. The sodium and water retention, which characteristically occurs in heart failure, illustrates the greater influence of the antinatriuretic (over the cardiac natriuretic) system, despite the large increase in the plasma concentrations of atrial natriuretic peptide. Indeed, the renal effects of exogenous atrial natriuretic peptide seem to be dramatically blunted in both human'" " and experiheart failure. The effects of 8-bromo-cGMP on renal excretory function are also abolished or greatly attenuated in experimental heart f a i l~r e . '~ This pathophysiological state is also characterised by increased vasoconstriction, which suggests an imbalance between vasoconstrictor and vasodilator systems. The tirst seems to be activated and the second to be depressed. The hypotensive effect of atrial natriuretic peptide is blunted in rats with myocardial infarction." Diminished endothelium derived relaxing factor activity has been reported in experirnentalI5 I6 and human" " heart failure. The results for plasma endothelium derived relaxing factor-NO concentrations (indirectly measured by its stable metabolite, NO,-) in patients with severe heart failure are conflicting.3x '' The impairment of both the endothelium dependent, and possibly the endothelium independent cGMP mediated vasodilation in patients with heart failure raises the question of the biological efficacy of the vasodilating factors in heart fai1~re.l~ '" These data raise the possibility that an intracellular defect beyond cGMP production is involved in the tolerance to atrial natriuretic peptide in heart failure. cCMP dependent kinase seems to mediate the effects of cGMP, and possibly also of CAMP, in smooth muscle cells." An increased cGMP dependent kinase activity has been reported in hypertensive rats." Our results show no change, however, in the arterial concentration of cGMP dependent kinase in rats with heart failure.
The concentration of cGMP, which is the second messenger of both NO and atrial natriuretic peptide, is raised in extracellular fluids, including plasma' and urine,"3 in heart failure. The presence of cGMP in extracellular fluids is believed to result from its egress through the cellular membrane, which is impermeable to its re-entry unless the molecules are modified to make them lipophilic ." This raises the questions of whether plasma cGMP mainly originates from a specific cell type, and the biological relevance of these increased plasma cGMP concentrations in heart failure. The plasma cGMP could come from endothelium or smooth muscle cells or from other cells. Cultured endothelial and vascular smooth muscle cells both release large amounts of cGMP and cAMP when stimulated by atrial natriuretic peptide and forskolin, respectively.# Nitric oxide activates the soluble guanylate cyclase of vascular smooth muscle, and also leads to increases in both intracellular and extracellular cGMP." 4'
The cellular heterogeneity of the organs makes it difficult to determine the in vivo state of the second messengers; however, large vessels, like the aorta, are mainly matrix and smooth muscle cells, with the endothelium limited to a single layer of cells. Conversely, the lung is particularly rich in capillaries, and so in endothelial cells. Thus the aortic cGMP concentrations probably reflect the cGMP concentration in smooth muscle cells, whereas the lung cGMP concentrations reflect the cGMP concentration in the endothelium. The cGMP concentrations in plasma and pleural effusions are one order of magnitude lower than the intracellular concentration, and thus cannot substantially influence the tissue concentration of cGMP.' 43 Therefore, tissue cGMP mainly reflects the intracellular content of the nucleotide. Endogenous plasma atrial natriuretic peptide was closely correlated to both plasma and pulmonary cGMP. This strongly suggests that plasma and pulmonary cGMP originate from stimulation of the particulate guanylate cyclase by atrial natriuretic peptide, and that endothelium is the main cell type involved in this phenomenon. This idea is supported by the effect of exogenous atrial natriuretic peptide on plasma and tissue cGMP in normal rats. An intravenous bolus of 3 p,g atrial natriuretic peptide.kg-' increased plasma atrial natriuretic peptide to a concentration close to that found in rats with severe myocardial infarction. Exogenous atrial natriuretic peptide induced similar increases in plasma and pulmonary cGMP content to that found in the model of heart failure. Phosphodiesterases do not seem to play a major part in regulating intracellular cGMP in the endothelium, as it lacks the two main phosphodiesterases involved in the degradation of cGMP.~* This might explain the large increase in pulmonary cGMP concentration in response to increased circulating atrial natriuretic peptide, and cGMP egression might predominantly contribute to the regulation of intracellular cGMP concentration in the endothelium. Similarly, the close correlation between plasma atrial natriuretic peptide and urinary cGMP is in agreement with the work of Wong et al; ' showing that increased urinary cGMP reflects the effect of atrial natriuretic peptide on the tubular cells. Lastly, cultured endothelial cells contain an active cAMP hydrolysing system?' which might account for the unchanging cAMP concentrations in lung and in plasma.
Cyclic GMP plays an important part in the relaxation of smooth muscle cells, and thus in vas~relaxation.~~ The cGMP in the thoracic and abdominal aorta in this model of heart failure was not different from sham operated rats, despite increased concentrations of atrial natriuretic peptide. Furthermore, intravenous atrial natriuretic peptide leading to comparable plasma atrial natriuretic peptide concentrations, failed to increase aortic cGMP content. Thus atrial natriuretic peptide within a pathophysiological range failed to influence aortic wall cGMP. As recently shown, aortic wall cGMP seems to be mainly dependent on NO synthase: soluble guanylate cyclase activity." Indeed, endothelium derived relaxing factor seems to be an ideal modulator of local vasomotor tone, because stimulation of its release integrates local (shear stress), neural (acetylcholine mediated), and hormonal (bradykinin, ADP, etc) signals.'" I ' Several reasons could account for the absence of change of aortic cGMP in response to increased circulating atrial natriuretic peptide. Firstly, atrial natriuretic peptide may be rapidly degraded by the clearance receptors and neutral endopeptidase on both endothelial and smooth muscle ~e l l s .~~-'~ Secondly, atrial natriuretic peptide could depress endothelium derived relaxing factor-NO activity, as suggested by in vitro leading to decreased soluble guanylate cyclase activity.'" Thirdly, at least two phosphodiesterases catabolise cGMP in vascular smooth muscle, and thus influence its c~ncentration.~' In summary, it is commonly assumed that the sympathetic adrenergic system and the renin angiotensin system are responsible for the increased peripheral vascular resistance in heart failure. The state of the vasodilatory systems in heart failure are, however, poorly defined. In this experimental model aortic and pulmonary cGMP concentrations were used as in vivo bioassays of circulating atrial natriuretic peptide and basal endothelium derived relaxing factor-NO activity. The pulmonary cGMP concentration was significantly higher in the rats with myocardial infarcts than in the control group. The increase in plasma, urinary, and pulmonary cGMP in rats with myocardial infarction was highly correlated with the increase in circulating atrial natriuretic peptide. By contrast, the aortic cGMP concentration was unchanged in these rats, despite high plasma atrial natriuretic peptide. In congestive heart failure a discrepancy seems to exist between pulmonary (mainly endothelium) and aortic wall (mainly smooth muscle cells) cGMP.
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